Armis Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

Armis Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-14,669	Closed	-$306K	–	408
2024 Q4	$306K	Buy	+14,669	New	+$315K	0.04%	265

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Armis Advisers's CPRX Position: Q1 2025 in Review

Armis Advisers sold out of Catalyst Pharmaceutical (CPRX) in Q1 2025, closing a stake of 14,669 shares — an estimated $306K sold.

Armis Advisers first reported a position in CPRX in Q4 2024 and held it in 1 quarter. The position peaked at $306K in Q4 2024. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

Armis Advisers reported no remaining Catalyst Pharmaceutical position as of Q1 2025 after selling out during the quarter.
Armis Advisers sold 14,669 Catalyst Pharmaceutical shares in Q1 2025, an estimated $306K.
Armis Advisers first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 1 quarter.
Armis Advisers's Catalyst Pharmaceutical position peaked at $306K in Q4 2024.
371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on Armis Advisers's 13F filing for Q1 2025, filed 8 May 2025.